Sorrento Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
8STN
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 67.15M 58.9M 54.55M 50.19M 94.93M 6.43B 96.78M 650M 255M 3.16B 252M 247M 10.9B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 133M 123M 113M 214M 14.52B 219M 1.47B 576M 7.13B 570M 557M 24.62B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | +19.20% |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 2011-03-31 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +19.20% | -0.67% | - | - | 381K | |
| +6.05% | +3.69% | +65.28% | +89.94% | 53.54B | |
| +0.21% | -6.28% | +56.18% | +127.90% | 54.18B | |
| +0.84% | -2.90% | +7.54% | +431.89% | 23.66B | |
| +0.81% | -3.79% | -18.27% | -16.19% | 22.78B | |
| +2.36% | +1.06% | +43.34% | -6.14% | 19.54B | |
| -2.29% | -1.92% | +35.57% | -29.14% | 17.82B | |
| -4.00% | -7.88% | +175.60% | +343.60% | 16.01B | |
| -1.15% | -4.83% | +46.53% | +627.30% | 15.37B | |
| -0.70% | -2.47% | +22.14% | +187.11% | 14.09B | |
| Average | +2.16% | -1.47% | +48.21% | +195.14% | 26.33B | |
| Weighted average by Cap. | +1.23% | -0.46% | +49.03% | +163.45% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 46.4M 42.98M 39.54M 74.8M 5.06B 76.25M 512M 201M 2.49B 199M 194M 8.59B | 62.84M 55.12M 51.05M 46.97M 88.84M 6.01B 90.57M 608M 239M 2.95B 236M 231M 10.2B |
| Net income | -428M -376M -348M -320M -606M -41B -617M -4.15B -1.63B -20.13B -1.61B -1.57B -69.53B | -573M -502M -465M -428M -810M -54.83B -826M -5.55B -2.18B -26.92B -2.15B -2.1B -92.99B |
| Net Debt | 111M 97.09M 89.92M 82.74M 156M 10.59B 160M 1.07B 420M 5.2B 416M 407M 17.97B | 84.53M 74.14M 68.67M 63.18M 120M 8.09B 122M 818M 321M 3.97B 317M 310M 13.72B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
